|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SMIM22 |
Gene summary for SMIM22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SMIM22 | Gene ID | 440335 |
| Gene name | small integral membrane protein 22 | |
| Gene Alias | CASIMO1 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | A0A1U9AC72 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 440335 | SMIM22 | GSM4909281 | Human | Breast | IDC | 4.95e-16 | -5.53e-01 | 0.21 |
| 440335 | SMIM22 | GSM4909285 | Human | Breast | IDC | 2.48e-26 | -6.19e-01 | 0.21 |
| 440335 | SMIM22 | GSM4909286 | Human | Breast | IDC | 6.10e-09 | -4.77e-01 | 0.1081 |
| 440335 | SMIM22 | GSM4909293 | Human | Breast | IDC | 1.22e-18 | 4.83e-01 | 0.1581 |
| 440335 | SMIM22 | GSM4909296 | Human | Breast | IDC | 3.52e-13 | 3.07e-01 | 0.1524 |
| 440335 | SMIM22 | GSM4909297 | Human | Breast | IDC | 5.43e-10 | 1.90e-02 | 0.1517 |
| 440335 | SMIM22 | GSM4909298 | Human | Breast | IDC | 6.76e-04 | 2.03e-01 | 0.1551 |
| 440335 | SMIM22 | GSM4909301 | Human | Breast | IDC | 1.06e-94 | 1.08e+00 | 0.1577 |
| 440335 | SMIM22 | GSM4909302 | Human | Breast | IDC | 2.67e-22 | 5.65e-01 | 0.1545 |
| 440335 | SMIM22 | GSM4909304 | Human | Breast | IDC | 1.07e-58 | 8.47e-01 | 0.1636 |
| 440335 | SMIM22 | GSM4909306 | Human | Breast | IDC | 3.84e-45 | 7.95e-01 | 0.1564 |
| 440335 | SMIM22 | GSM4909307 | Human | Breast | IDC | 3.00e-03 | 2.99e-01 | 0.1569 |
| 440335 | SMIM22 | GSM4909308 | Human | Breast | IDC | 1.40e-05 | 2.33e-01 | 0.158 |
| 440335 | SMIM22 | GSM4909311 | Human | Breast | IDC | 9.07e-37 | 3.77e-01 | 0.1534 |
| 440335 | SMIM22 | GSM4909312 | Human | Breast | IDC | 1.96e-12 | 3.74e-01 | 0.1552 |
| 440335 | SMIM22 | GSM4909313 | Human | Breast | IDC | 4.20e-22 | 6.52e-01 | 0.0391 |
| 440335 | SMIM22 | GSM4909317 | Human | Breast | IDC | 6.58e-12 | 5.12e-01 | 0.1355 |
| 440335 | SMIM22 | GSM4909318 | Human | Breast | IDC | 9.81e-04 | 5.16e-01 | 0.2031 |
| 440335 | SMIM22 | GSM4909319 | Human | Breast | IDC | 4.77e-49 | 4.07e-01 | 0.1563 |
| 440335 | SMIM22 | GSM4909320 | Human | Breast | IDC | 6.76e-22 | 7.16e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
| GO:00329709 | Breast | Precancer | regulation of actin filament-based process | 42/1080 | 397/18723 | 1.11e-04 | 2.01e-03 | 42 |
| GO:00329569 | Breast | Precancer | regulation of actin cytoskeleton organization | 36/1080 | 358/18723 | 8.56e-04 | 9.88e-03 | 36 |
| GO:003297014 | Breast | IDC | regulation of actin filament-based process | 56/1434 | 397/18723 | 6.37e-06 | 1.99e-04 | 56 |
| GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
| GO:003295614 | Breast | IDC | regulation of actin cytoskeleton organization | 48/1434 | 358/18723 | 1.03e-04 | 1.96e-03 | 48 |
| GO:003297024 | Breast | DCIS | regulation of actin filament-based process | 56/1390 | 397/18723 | 2.50e-06 | 8.74e-05 | 56 |
| GO:005123523 | Breast | DCIS | maintenance of location | 47/1390 | 327/18723 | 9.55e-06 | 2.56e-04 | 47 |
| GO:003295624 | Breast | DCIS | regulation of actin cytoskeleton organization | 48/1390 | 358/18723 | 4.82e-05 | 9.92e-04 | 48 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:003295615 | Cervix | HSIL_HPV | regulation of actin cytoskeleton organization | 33/737 | 358/18723 | 5.61e-06 | 2.09e-04 | 33 |
| GO:003297015 | Cervix | HSIL_HPV | regulation of actin filament-based process | 35/737 | 397/18723 | 7.87e-06 | 2.81e-04 | 35 |
| GO:005123514 | Cervix | HSIL_HPV | maintenance of location | 26/737 | 327/18723 | 5.67e-04 | 8.04e-03 | 26 |
| GO:005123524 | Cervix | N_HPV | maintenance of location | 33/534 | 327/18723 | 3.40e-10 | 2.21e-07 | 33 |
| GO:003297025 | Cervix | N_HPV | regulation of actin filament-based process | 27/534 | 397/18723 | 3.03e-05 | 8.02e-04 | 27 |
| GO:003295625 | Cervix | N_HPV | regulation of actin cytoskeleton organization | 22/534 | 358/18723 | 6.55e-04 | 8.42e-03 | 22 |
| GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
| GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SMIM22 | SNV | Missense_Mutation | novel | c.203N>A | p.Pro68His | p.P68H | K7EJ46 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |